Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Digoxin-macrolide drug interaction

E D Bizjak1, V F Mauro

  • 1College of Pharmacy, University of Toledo, OH 43606, USA.

The Annals of Pharmacotherapy
|September 20, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.

The Annals of pharmacotherapy·2001
Same author

Impact of oral bases on aluminum absorption.

American journal of therapeutics·2001
Same author

Spironolactone in the treatment of congestive heart failure.

The Annals of pharmacotherapy·2000
Same author

A hypertensive reaction induced by concurrent use of selegiline and dopamine.

The Annals of pharmacotherapy·2000
Same author

Dofetilide: a class III-specific antiarrhythmic agent.

The Annals of pharmacotherapy·2000
Same author

Procainamide-induced psychosis: a case report and review of the literature.

The Annals of pharmacotherapy·1999
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

Macrolide antibiotics can increase digoxin levels in the body by affecting gut bacteria. This drug interaction may lead to potential digoxin toxicity in some patients.

Area of Science:

  • Pharmacology
  • Microbiology
  • Internal Medicine

Background:

  • Digoxin is a cardiac glycoside used to treat heart failure and arrhythmias.
  • Gastrointestinal flora metabolize digoxin into inactive dihydro metabolites.
  • Alterations in this metabolism can affect digoxin's efficacy and safety.

Purpose of the Study:

  • To investigate the potential interaction between macrolide antibiotics and digoxin.
  • To understand the mechanism by which macrolides affect digoxin bioavailability.
  • To assess the clinical significance of this drug interaction.

Main Methods:

  • Review of existing literature on macrolide-digoxin interactions.
  • Analysis of pharmacokinetic and pharmacodynamic data.
  • Clinical case study review (if applicable, though not explicitly stated in abstract).

Related Experiment Videos

Main Results:

  • Macrolide antibiotics (erythromycin, clarithromycin, roxithromycin) can enhance oral digoxin bioavailability.
  • This enhancement is attributed to the alteration of gastrointestinal flora that metabolize digoxin.
  • Increased serum digoxin concentrations may occur, posing a risk of toxicity.

Conclusions:

  • Macrolide antibiotics represent a potential risk factor for increased digoxin levels.
  • This interaction can be clinically significant, potentially affecting up to 10% of the population.
  • Caution is advised when co-administering macrolides with digoxin, especially in patients stabilized on digoxin therapy.